Vistagen Therapeutics, Inc. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 62/100
What the filing says
Vistagen announced FY2027 Q1 results (ended June 30, 2026): fasedienol failed its primary endpoint in PALISADE-4 Phase 3 trial but showed nominally significant improvement in a post-hoc subgroup of very severe social anxiety patients. The company reported Q1 net loss of $13.0M (vs. $15.1M prior year), cash of $31.7M (down from $30.8M at March 31, 2026), and R&D expense of $10.9M. Leadership additions: Angel Angelov appointed CMO; Douglas Williamson joined Board. FDA engagement planned this quarter to discuss potential registration pathway; cash runway extends into 2027 but insufficient beyond one year.
Why this rating
Failed primary endpoint is negative; post-hoc subgroup signal offers slim hope but is not powered and speculative. Cash burn ($13M/quarter) vs. $31.7M reserve creates 2–3 quarter runway. For a $137.7M market-cap company, this existential cash pressure and regulatory uncertainty are material, though not yet fatal.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.